Fuse Diagnostics, United Kingdom
https://fuse-dx.com

Fuse Diagnostics is developing a rapid, instrument-free diagnostic for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The test, Apex CT/NG, utilizes innovative device designs and molecular technologies with the potential to deliver accuracy that is equivalent to lab-based PCR systems in an ultra-rapid, low-cost format ideally suited to flexible global deployment, including areas with remote access to secondary healthcare in low- and middle-income countries (LMICs).

Apex CT/NG is positioned to improve current testing options, as the diagnostic’s instrument-free design aims to increase access to CT/NG diagnosis and appropriate treatment through reducing logistical complexity caused by centralized laboratory testing and the operational constraints of instrument-based platforms.

Gonorrhea, caused by Neisseria gonorrhoeae, is the second-most reported bacterial sexually transmitted infection, infecting approximately 82 million people globally in 2020, with the burden highest in LMICs. Patients with gonorrhea may experience serious health effects, including pelvic inflammatory disease, chronic pain, and infertility. Untreated gonorrhea can spread to the blood stream, which can be life threatening, and increase the risk of HIV infection. The true burden of gonorrhea may be greater than reported cases since patients do not always exhibit symptoms.

Current Development Stage: Feasibility

CARB-X Investment: US$1M

Initial CARB-X Investment Date: March 1, 2024